Sengupta Subhasish, Modak Prasenjit, McCauley Noreen, O'Donnell Luke J D
Department of Gastroenterology, Mayo General Hospital, Castlebar, Ireland.
Eur J Gastroenterol Hepatol. 2007 Jul;19(7):581-3. doi: 10.1097/MEG.0b013e32811ec044.
The effects of cholinergic agents and vagal control on gall-bladder motility are well defined. Alpha adrenergic antagonists have been found in previous studies to have a prokinetic effect on gall-bladder motility in normal human patients. Their effects have not, however, been fully elucidated in patients with gall-stone disease.
Our aim was to determine the effects of alpha-antagonists and beta-antagonists on gall-bladder motility in human patients with gall-stone disease.
In this single-blind, three-way crossover study, a slow release formulation of 80 mg propranolol (beta-antagonist), and 25 mg indoramin (alpha-antagonist), and placebo were administered separately to 10 patients with gall-stone disease on three separate days 8 h before assessment of gall-bladder volumes by ultrasonography. Gall-bladder volumes were assessed in the fasting state and at 5 min intervals for 50 min after a standard proprietary enteral feed (Ensure 180 ml, Abbott). Differences between the placebo and postadrenergic antagonist scan volumes were tested using the Wilcoxon-signed rank test.
There were no significant differences in the mean fasting gall-bladder volumes after receiving propranolol, indoramin and placebo (23.6+/-3.9, 22.3+/-4.3, 26.8+/-7.2 ml, mean+/-SEM, respectively). In the postprandial period, however, indoramin significantly enhanced postprandial gall-bladder emptying compared with placebo between 5 and 30 min (P<0.05) after which refilling commenced. There were no significant postprandial gall-bladder volume differences between propranolol and placebo.
Indoramin, an alpha-adrenergic antagonist, acts as a prokinetic agent enhancing postprandial gall-bladder emptying in patients with gall-stone disease. This effect is similar to its effect on postprandial gall-bladder emptying in healthy individuals.
胆碱能药物和迷走神经控制对胆囊运动的影响已得到充分明确。在先前的研究中发现,α肾上腺素能拮抗剂对正常人类患者的胆囊运动具有促动力作用。然而,它们在胆结石疾病患者中的作用尚未完全阐明。
我们的目的是确定α拮抗剂和β拮抗剂对胆结石疾病患者胆囊运动的影响。
在这项单盲、三向交叉研究中,在通过超声检查评估胆囊体积前8小时,分别于三个不同日期给10例胆结石疾病患者服用80毫克普萘洛尔(β拮抗剂)缓释制剂、25毫克吲哚拉明(α拮抗剂)和安慰剂。在空腹状态下以及在给予标准专利肠内营养剂(安素180毫升,雅培公司)后每隔5分钟评估一次胆囊体积,共评估50分钟。使用Wilcoxon符号秩检验来测试安慰剂与肾上腺素能拮抗剂扫描后体积之间的差异。
接受普萘洛尔、吲哚拉明和安慰剂后,平均空腹胆囊体积无显著差异(分别为23.6±3.9、22.3±4.3、26.8±7.2毫升,平均值±标准误)。然而,在餐后期间,与安慰剂相比,吲哚拉明显著增强了餐后5至30分钟的胆囊排空(P<0.05),之后开始重新充盈。普萘洛尔与安慰剂之间餐后胆囊体积无显著差异。
α肾上腺素能拮抗剂吲哚拉明作为一种促动力剂,可增强胆结石疾病患者餐后胆囊排空。这种作用与其对健康个体餐后胆囊排空的作用相似。